Citi: Adds WuXi Biologics (02269.HK) to 90-day upside catalyst watch list; expects full-year guidance may be raised in Q4.

Zhitong Finance APP has learned that Citi issued a research report stating that it has added WuXi Biologics (02269.HK) to its 90-day upside catalyst watch list. The bank believes that the company may raise its overall guidance in the fourth quarter, and the biosimilar development agreement reached with Fresenius may also prompt the company to raise its long-term target for contract manufacturing organization (CMO) revenue. Citi stated that WuXi Biologics is also one of its preferred AI-driven drug discovery (AIDD) beneficiary stocks, and believes that the company's AIDD capabilities are currently being undervalued by the market.